4-(2,6-dimethyl-phenoxy)-phthalic acid 、 聚甘氨酸 以
水 为溶剂,
反应 0.5h,
以to give the title compound as a dark glass (yield: 99%)的产率得到[5-(2,6-dimethyl-phenoxy)-1,3-dioxo-1,3-dihydro-isoindol-2-yl]-acetic acid
参考文献:
名称:
CYANOISOQUINOLINE COMPOUNDS AND METHODS OF USE THEREOF
Novel nitrogen-containing heteroaryl compounds and methods of use thereof
申请人:FibroGen, Inc.
公开号:US20040254215A1
公开(公告)日:2004-12-16
The present invention relates to compounds suitable for use in mediating hypoxia inducible factor and for treating erythropoietin-associated conditions by increasing endogenous erythropoietin in vitro and in vivo.
[EN] NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND THEIR USE IN INCREASING ENDOGENOUS ERYTHROPOIETIN<br/>[FR] COMPOSES HETEROARYLIQUES CONTENANT DE L'AZOTE ET LEUR UTILISATION DANS L'AUGMENTATION DE L'ERYTHROPOIETINE ENDOGENE
申请人:FIBROGEN INC
公开号:WO2004108681A1
公开(公告)日:2004-12-16
The present invention relates to compounds suitable for use in mediating hypoxia inducible factor and for treating erythropoietin-associated conditions by increasing endogenous erythropoietin in vitro and in vivo.
Nitrogen-containing heteroaryl compounds and methods of use thereof
申请人:Fibrogen, Inc.
公开号:US07323475B2
公开(公告)日:2008-01-29
The present invention relates to compounds suitable for use in mediating hypoxia inducible factor and for treating erythropoietin-associated conditions by increasing endogenous erythropoietin in vitro and in vivo.
NOVEL NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF
申请人:Arend Michael P.
公开号:US20080293763A1
公开(公告)日:2008-11-27
The present invention relates to compounds suitable for use in mediating hypoxia inducible factor and for treating erythropoietin-associated conditions by increasing endogenous erythropoietin in vitro and in vivo.
Novel Nitrogen-Containing Heteroaryl Compounds And Methods of Use Thereof
申请人:AREND P. Michael
公开号:US20070185159A1
公开(公告)日:2007-08-09
The present invention relates to compounds suitable for use in mediating hypoxia inducible factor and for treating erythropoietin-associated conditions by increasing endogenous erythropoietin in vitro and in vivo.